Key Points The growth hormone (GH)insulin-like growth factor (IGF) axis consists of central neuro-anatomical, regulatory and genetic systems, and the peripheral intracellular GH signalling pathway The introduction of recombinant human GH (rhGH) in 1985 ended the phase of pituitary-derived human growth hormone (hGH) and its associated limitations and risks, opening the possibility of widespread clinical use GH deficiency (GHD) is a syndrome with many different causes and is associated with alterations in growth, body composition and metabolism In some non-GHD short stature disorders, rhGH has been proved effective and is used as a surrogate for the currently unknown, pathophysiologically appropriate treatment Risks of hGH therapy might relate to its direct effects on growth, its anti-insulin action and its cell-proliferating activity
Choose options The Wolverine Stack 2.0 adds a longevity peptide to the original recovery pair
GHK-Cu (Copper Tripeptide-1) is a naturally occurring copper-binding peptide complex studied for its role in tissue remodeling, collagen signaling, cellular repair pathways, and sin regeneration mechanisms
Rights and permissions About this article Cite this article Hassan, O.K., Hayawi, M.A., Shareef, A.S
